News | September 12, 2025
A.forall expands US generics portfolio
Four FDA-approved products strengthen portfolio and reaffirm commitment to global reach
Four FDA-approved products strengthen portfolio and reaffirm commitment to global reach
The approval clears the company to market a generic version that is therapeutically equivalent to Retin-A Cream
Company expands injectable portfolio with therapeutically equivalent version of Vimpat®, targeting a market valued at approximately $15.2 million annually
The approved product is the generic equivalent of Sutab® Tablets developed by Azurity Pharmaceuticals
Approved product is therapeutically equivalent to Synthroid of AbbVie and is indicated for the treatment of congenital or acquired hypothyroidism
US formulations grew 11% to Rs. 564 crore as Alembic enters US branded pharmaceuticals market with launch of Pivya
Antiviral injection addressing CMV and HSV infections had US market sales of nearly $15 million in the last 12 months
FY26 revenue rises 17% to Rs. 5,453 crore as US generics business jumps 49% and adjusted EBITDA margin improves to 26% for the quarter
Fresenius Kabi's approved generic therapy addresses acute symptomatic hypocalcemia and targets a US market valued at nearly $71 million
Analysts expect modest revenue growth but pressure on profitability in the March quarter
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
